富含白的重复含有15作为宫癌的潜在标记物和治疗标
Thi Hai Ly Dao1, Keiichiro Nakamura2, Kazuhiro Okamoto1
1Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Anticancer research
|November 29, 2025
概括
富含白的重复含有15 (LRRC15) 与较差的宫癌 (CC) 预后和淋巴血管空间参与有关. 抑制LRRC15增强了细胞亡,表明其作为CC的治疗点的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 氨酸丰富的重复含有15 (LRRC15) 是一种与癌症相关纤维细胞 (CAFs) 相关的新型标记物.
- 在宫癌 (CC) 中LRRC15的作用和临床意义尚不清楚.
研究的目的:
- 研究LRRC15在宫癌中的表达,临床意义和功能作用.
- 探索LRRC15作为CC的潜在治疗点.
主要方法:
- 在正常的宫和CC组织中对LRRC15表达的RT-qPCR分析.
- 对LRRC15表达与临床病理参数和患者预后的相关性分析.
- 在CC细胞系中对LRRC15的功能研究,包括淘汰实验和信号通路分析.
主要成果:
- 在CC患者中,LRRC15的表达与淋巴血管空间参与有显著的相关性.
- 高LRRC15表达与CC中较差的无进展生存率有关.
- 不管HPV的状况如何,LRRC15的淘汰抑制了WNT和FAK信号传递,增加了Caspase3/7的表达,并促进了CC细胞的亡.
结论:
- LRRC15表达作为预后标志物用于宫癌中较差的结果.
- LRRC15代表了宫癌治疗的有前途的治疗标.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:39lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K